Evidence map›Paper›PMID 40293195›Full record

ReviewACS applied bio materials2025

Manganese-Based Nanotherapeutics for Targeted Treatment of Breast Cancer.

Mubassir Khan, Razi Ullah, Syed Mubassir Shah, Umar Farooq, Jun Li

Abstract readReview
In one paragraph

Review in ACS applied bio materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mubassir KhanKey Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, P.R. China.
Razi UllahKey Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Lab for Vascular Implants, College of Bioengineering, Chongqing University, Chongqing 400030, China.ORCID 0000-0003-0449-5568
Syed Mubassir ShahDepartment of Biotechnology, Abdul Wali Khan University, KPK, Mardan 23200, Pakistan.
Umar FarooqJinfeng Laboratory, No. 313 Jinyue Road, High-tech Zone, Chongqing 401329, China.
Jun LiJinfeng Laboratory, No. 313 Jinyue Road, High-tech Zone, Chongqing 401329, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is one of the most common cancers among women and is associated with high mortality. Traditional modalities, including surgery, radiotherapy, and chemotherapy, have achieved certain advancements but continue to combat challenges including harm to healthy tissues, resistance to treatment, and adverse drug reactions. The rapid advancements in nanotechnology recently facilitated the exploration of innovative strategies for breast cancer therapy. Manganese-based nanotherapeutics have attracted great attention because of their unique characteristics such as tunable structures/morphologies, versatility, magnetic/optical properties, strong catalytic activities, excellent biodegradability, and biocompatibility. In this review, we highlighted different types of Mn-based nanotherapeutics to modulate TME, including metal-immunotherapy, alleviating tumor hypoxia, and increasing reactive oxygen species production, and we emphasized its role in magnetic resonance imaging (MRI)-guided therapy, photoacoustic imaging, and theranostic-based therapy along with a therapeutic carrier, all of which were discussed in the context of breast cancer. Hopefully, the present review will provide insights into the current landscape and future directions of multifunctional applications of Mn-based nanotherapeutics in the field of breast cancer treatment.

Indexed as

Antineoplastic AgentsBiocompatible MaterialsBreast NeoplasmsManganeseAnimalsFemaleHumansMaterials TestingAntineoplastic AgentsBiocompatible MaterialsManganeseBreast cancermanganesenanoparticlesreactive oxygen speciestumor hypoxiatumor microenvironment

Identifiers

PMID40293195
PMCPMC12094176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.